Last Week in Biomedicine
di TrialBreaks
Last Week in Biomedicine | Jun 29–Jul 3 | Part 2 of 2: Baby Pompe…
Informazioni su questo podcast
Every Tuesday, we break down 10 of the most significant biopharma stories and buzzworthy clinical trial breakthroughs from the previous week. The podcast highlights major Phase 2 and Phase 3 trial results, breakthrough therapies, biotech innovations, FDA updates, and emerging treatments shaping the future of medicine. From obesity and cancer to autoimmune disease, neurodegeneration, cardiovascular disease, diabetes, and rare genetic disorders, each episode delivers a fast, accessible look at the data, discoveries, and therapies driving the next generation of healthcare.
Episodi
- Last Week in Biomedicine | Jun 29–Jul 3 | Part 2 of 2: Baby Pompe Disease Trial, DLBCL Combo Win · 37 minPart 2 covers three more standout stories from the same week: a Phase 3 trial that gives babies with a devastating enzyme disease a fighting chance, a first-of-its-kind cell…
- Last Week in Biomedicine | Jun 29–Jul 3 | Part 1 of 2: CRISPR for Toddlers, KRAS Lung Cancer Win · 44 minCRISPR gene editing crossed a major line this week: the FDA now allows Casgevy — the first CRISPR therapy of any kind — for children as young as 2 with sickle cell disease…
- Last Week in Biomedicine | June 22–26 | Part 2 of 2: Thyroid Eye Disease, ADHD + Anxiety, Skyrizi Kids · 41 minPart 2 covers a new drug for the bulging-eye autoimmune disease, the first Phase 3 ADHD trial designed for patients who also have anxiety, and a major pediatric expansion for a…
- Last Week in Biomedicine | June 22–26 | Part 1 of 2: LSD Depression Phase 3, Trodelvy TNBC Approval · 37 minThis week, an LSD-based therapy hit its main goal in a Phase 3 depression trial — and two huge breast cancer approvals landed at the FDA on the same week. In Part 1 we cover: 1…
- Last Week in Biomedicine | June 14–20 | Part 2 of 2: Mezigdomide Myeloma, HCM Heart Drug · 25 minPart 2 of our week of June 14–20, 2026 wrap-up covers a new molecular glue for relapsed multiple myeloma that cut disease progression by half, a heart drug that may finally work…
- Last Week in Biomedicine | June 14–20 | Part 1 of 2: CRISPR HAE Cure, Narcolepsy Orexin Breakthrough · 35 minThis week opened with one of the most significant gene-editing milestones in clinical medicine: a single CRISPR infusion cut hereditary angioedema attacks by 87 percent in a…
- Last Week in Biomedicine | June 6–13 | Part 2 of 2: CagriSema Diabetes, Sickle Cell Plenary · 21 minPart 2 of our June 6–13 wrap-up: Novo Nordisk's CagriSema beats semaglutide alone in three Phase 3 diabetes trials, Takeda's zasocitinib pill outperforms Sotyktu head-to-head in…
- Last Week in Biomedicine | June 6–13 | Part 1 of 2: Retatrutide Weight Loss, Weekly HIV Pill · 21 minA blockbuster week in biomedicine — Eli Lilly's retatrutide produced weight loss approaching bariatric surgery in Phase 3, and Gilead and Merck's once-weekly oral HIV pill…
- Last Week in Biomedicine | May 30 – Jun 5 | Part 2 of 2: Talzenna Prostate Combo, IgG4 Disease First · 16 minFrom a prostate cancer combo that uses your tumor's own broken DNA-repair against it, to the first drug ever to succeed in a rare autoimmune disease called IgG4-related disease —…
- Last Week in Biomedicine | May 30 – Jun 5 | Part 1 of 2: Daraxonrasib Pancreatic Cancer, Ivonescimab Lung · 21 minThe biggest week in cancer research of 2026 dropped at the ASCO meeting in Chicago, and one drug stole the show: a new RAS-blocking pill that nearly doubled survival in…
- Last Week in Biomedicine | May 23–29 | Part 2 of 2: Apogee Eczema, TG Therapeutics MS · 11 minIn Part 2 we cover the remaining clinical trial readouts from the week of May 23–29, 2026 — a Phase 2 atopic dermatitis breakthrough and a Phase 3 multiple sclerosis convenience…
- Last Week in Biomedicine | May 23–29 | Part 1 of 2: BMS Myeloma, GSK Hep B Cure, Pfizer Lung Cancer · 36 minIn Part 1 we cover the three biggest clinical trial readouts from the week of May 23–29, 2026 — including two ASCO 2026 opening-day announcements that reshape oncology. 1…
- Last Week in Biomedicine | May 18–22 | Part 2 of 2: Bladder Cancer Conjugate, HPV Cervical Win · 12 minPart 2 of our May 18–22, 2026 roundup digs into a first-in-class Bicycle Toxin Conjugate for bladder cancer, a non-surgical DNA immunotherapy clearing HPV-driven cervical…
- Last Week in Biomedicine | May 18–22 | Part 1 of 2: Retatrutide Obesity, Sac-TMT Cancer Win · 20 minThis week the biggest story in clinical trial results came out of an obesity trial: Eli Lilly's retatrutide — a once-weekly shot that activates three different…
- Last Week in Biomedicine | May 11–15 | Part 2 · 23 minTop 10 significant clinical trial results from last week Part 2: 6. Enterprise Therapeutics (private) — ETD001 (inhaled ENaCblocker) for cystic fibrosis (Phase 2) 7. Daré…
- Last Week in Biomedicine | May 11–15 | Part 1 · 13 minTop 10 significant clinical trial results from last week Part 1: 1. REGENXBIO ($RGNX) — RGX-202 microdystrophin gene therapy for Duchenne muscular dystrophy (Phase 3) 2. Alkermes…
- Last Week in Biomedicine | May 4-9 · 30 minLast week's biggest biotech story: Cytokinetics hit both dual primary endpoints in the ACACIA-HCM pivotal Phase 3 trial of aficamten in non-obstructive hypertrophic…








